Last reviewed · How we verify
NCT06569589: SSTT
Tissue Sodium Quantification in Patients With Primary Aldosteronism: See Sodium to Treat
trial testing 23NaMRI Scan in Hypertension in 80 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Jens Titze |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 27 December 2023 |
| Primary completion | 31 March 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 4 locations across Singapore |
Drugs / interventions tested
- 23NaMRI Scan
- Potassium Chloride (KCl)
Conditions studied
- Hypertension — all drugs for Hypertension →
- Primary Aldosteronism — all drugs for Primary Aldosteronism →
- Hypokalemia — all drugs for Hypokalemia →
Sponsor
Jens Titze
Who can join
Adults 21 to 70, any sex, with Hypertension or Primary Aldosteronism. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to provide quantitative facts on the pathophysiological changes in tissue Na+ content during Na+/K+ redistribution disorders in patients with PA in response to standard therapy. The investigators hypothesize that patients with primary aldosteronism have excessive Na+ storage in the muscle, which can now be quantified non-invasively using 23NaMRI. In analogy to the role of HbA1c as a metabolic long-term marker in diabetes, the quantifiable changes in muscle Na+ content may deliver the data evidence necessary to justify and conduct randomized diagnostic endpoint outcome trials in the future, with the ultimate aim to improve PA detection rate and treatment.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
MON-298 Adrenal artery embolization for bilateral primary aldosteronism
· 2025 -
MON-297 Long Term Renal Outcomes In Patients With Primary Aldosteronism
· 2025 -
MON-296 Tissue Sodium Content For Differential Diagnosis Of Essential Hypertension Versushyperaldosteronism: Baseline Characteristics Of The “See-Sodium-To-Treat (SSTT)” Trial
· 2025
Verify or expand the search:
- PubMed search for NCT06569589
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypertension
Currently open trials in the same condition.
- NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
- NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
- NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting
Other Jens Titze trials
Trials by the same sponsor.
- NCT04319068 — Sodium Storage in Singaporeans · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06569589 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jens Titze
- Last refreshed: 6 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06569589.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing